GlassScriptPhysician profile
Jeffrey M Shoss
NPI 1851616767
$4,490.98
in general payments reported to CMS, 2019-2025
36 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $56.80 · 2021: $152 · 2022: $615 · 2023: $870 · 2024: $1,154 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $700.95 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Boston Scientific Corporation | $542.85 | 2019-2024 | Lithovue, Rezum Generator |
| Procept Biorobotics Corporation | $459.90 | 2022-2025 | Aquabeam Robotic System, Aquabeam System |
| Astellas Pharma US INC | $212.65 | 2019-2024 | Xtandi |
| Dendreon Pharmaceuticals LLC | $210.54 | 2023-2025 | Provenge |
| Olympus America INC. | $200.46 | 2023-2025 | Itind System |
| Coloplast Corp | $197.21 | 2021-2025 | Titan, Porges Coloplast |
| Merck Sharp & Dohme LLC | $180.57 | 2022-2024 | Lynparza, Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $176.08 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $161.47 | 2023-2025 | Orgovyx, Gemtesa |
| Intuitive Surgical, INC. | $141.69 | 2019 | |
| Abbvie INC. | $130.36 | 2021-2025 | Botox |
| Progenics Pharmaceuticals, INC. | $119.98 | 2022 | |
| Pfizer INC. | $102.40 | 2025 | |
| Ferring Pharmaceuticals INC. | $100.16 | 2024-2025 | Adstiladrin |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $93.45 | 2021-2022 | |
| Medtronic, INC. | $89.14 | 2023-2025 | Interstim, Emprint |
| Novartis Pharmaceuticals Corporation | $87.15 | 2023-2025 | |
| Tempus Ai, INC | $74.29 | 2024 | |
| Axonics, INC. | $73.10 | 2022-2023 | Bulkamid, Axonics |
| Teleflex LLC | $46.63 | 2021-2022 | |
| Antares Pharma, INC. | $45.01 | 2019-2024 | Xyosted |
| Endo USA, INC. | $44.04 | 2024 | Xiaflex |
| Cook Medical LLC | $41.66 | 2020-2024 | Resonance |
| Immunitybio, INC. | $34.65 | 2025 | |
| Caris Mpi, INC. | $29.70 | 2025 | Mi Cancer Seek |
| Endo Pharmaceuticals INC. | $24.54 | 2023 | Aveed, Xiaflex |
| Veloxis Pharmaceuticals, INC. | $23.18 | 2020 | |
| Myovant Sciences INC. | $22.37 | 2022 | |
| Integra Lifesciences Corporation | $22.22 | 2023 | Cusa Clarity, Codman Certas, Codman Hakim |
| La Jolla Pharmaceutical Company | $20.40 | 2019 | |
| Foundation Medicine, INC. | $18.40 | 2022 | |
| Telix Pharmaceuticals | $17.46 | 2023 | Illuccix |
| Ethicon US, LLC | $17.38 | 2023 | Echelon Flex |
| Astrazeneca Pharmaceuticals LP | $15.53 | 2022 | |
| Neotract INC. | $13.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Shoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.